Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Recruiting now · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.

Key facts

Study ID

NCT06558227

Run by

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

People needed

90

Starts

2024-10-24

Expected to finish

2026-10-01

Last updated by the study team

2024-12-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fully understand the study and voluntarily sign the informed consent form.
• 18-75 years of age;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；
• Life expectancy ≥ 12 weeks.

You may not qualify if…

• Patients were deemed unsuitable for participating in the study by the investigator for any reasons.

Where it is running

• West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.